Research Article
Reduced Duration of Postchikungunya Musculoskeletal Pain in Rheumatological Patients Treated with Biologicals
Table 1
Clinical and demographic data comparing the group with rheumatologic disease using bDMARDs and the control group.
| | | bDMARD (N = 168) | Control (N = 56) | value |
| | Age (mean. ± SD)# | 50.68 (12.86) | 48.47 (16.85) | 0.314 | | Sex—N (%) | | | | | Female | 113 (67) | 29 (52) | 0.055 | | Male | 55 (33) | 27 (48) | | | Comorbidities—N (%) | 134 (80) | 32 (57) | 0.001 | | Hypertension | 65 (39) | 14 (25) | 0.231 | | Diabetes | 24 (14) | 9 (16) | 0.359 | | Psoriasis | 18 (11) | 0 (0) | 0.026 | | Respiratory disease | 20 (12) | 3 (5) | 0.405 | | Smoking | 6 (4) | 7 (13) | 0.002 | | Cardiovascular disease | 11 (6.5) | 5 (9) | 0.341 | | Renal disease | 4 (2) | 2 (4) | 0.610 | | Inflammatory bowel disease | 7 (4) | 0 (0) | 0.190 | | Rheumatologic diagnosis—N (%) | | | | | Rheumatoid arthritis | 94 (56) | — | — | | Ankylosing spondylitis | 44 (26) | — | — | | Psoriatic arthritis | 18 (11) | — | — | | Spondyloarthritis | 8 (5) | — | — | | Psoriasis | 2 (1) | — | — | | Uveitis/Behçet disease | 2 (1) | — | — | | bDMARD—N (%) | 168 (100) | — | — | | Anti-TNFc | 116 (69) | — | — | | Others | 52 (31) | — | — | | sDMARD—N (%) | 71 (42) | — | — | | Methotrexate | 49 (29) | — | — | | Leflunomide | 17 (10) | — | — | | Sulfasalazine | 5 (3) | — | — | | Prednisone | 49 (29) | — | — | | CHIK symptoms | 51 (30) | 21 (37) | 0.397 | | Musculoskeletal symptoms | | | | | <3 months | 36 (21) | 12 (21) | 0.222 | | >3 months | 15 (9) | 9 (16) | | | Pain pattern | | | | | Persistent | 21 (13) | 8 (14) | 0.835 | | Polyarticular | 38 (22) | 14 (25) | 0.510 | | Anti-CHIKV IgG | | | | | Positive | 42 (25) | 15 (27) | 0.79 | | Negative | 126 (75) | 41 (73) |
|
|
TNF: tumor necrosis factor; bDMARD: biological disease-modifying antirheumatic drug. #t-test; infliximab, etanercept, adalimumab, golimumab, or certolizumab; abatacept, rituximab, tocilizumab, or secukinumab. |
